These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 34460053)

  • 21. New proapoptotic chemotherapeutic agents based on the quinolone-3-carboxamide scaffold acting by VEGFR-2 inhibition.
    El-Fakharany ZS; Nissan YM; Sedky NK; Arafa RK; Abou-Seri SM
    Sci Rep; 2023 Jul; 13(1):11346. PubMed ID: 37443185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting VEGFR-2 by new quinoxaline derivatives: Design, synthesis, antiproliferative assay, apoptosis induction, and in silico studies.
    Alsaif NA; Mahdy HA; Alanazi MM; Obaidullah AJ; Alkahtani HM; Al-Hossaini AM; Al-Mehizi AA; Elwan A; Taghour MS
    Arch Pharm (Weinheim); 2022 Feb; 355(2):e2100359. PubMed ID: 34862634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
    Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
    Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis of novel nicotinic acid derivatives of potential antioxidant and anticancer activity.
    El-Dash Y; Khalil NA; Ahmed EM; Hassanin SO; Gowifel AMH; Hassan MSA
    Arch Pharm (Weinheim); 2023 Dec; 356(12):e2300250. PubMed ID: 37792247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis, molecular docking, in silico ADMET profile and anticancer evaluations of sulfonamide endowed with hydrazone-coupled derivatives as VEGFR-2 inhibitors.
    Sayed AM; Taher FA; Abdel-Samad MRK; El-Gaby MSA; El-Adl K; Saleh NM
    Bioorg Chem; 2021 Mar; 108():104669. PubMed ID: 33515863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
    Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
    Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis, and molecular docking of novel 2-arylbenzothiazole multiangiokinase inhibitors targeting breast cancer.
    Abdel-Mohsen HT; Abd El-Meguid EA; El Kerdawy AM; Mahmoud AEE; Ali MM
    Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900340. PubMed ID: 32045054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis, and antitumor screening of new thiazole, thiazolopyrimidine, and thiazolotriazine derivatives as potent inhibitors of VEGFR-2.
    Abd Elhameed AA; Ali AR; Ghabbour HA; Bayomi SM; El-Gohary NS
    Drug Dev Res; 2023 Dec; 84(8):1664-1698. PubMed ID: 37661648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modified Benzoxazole-Based VEGFR-2 Inhibitors and Apoptosis Inducers: Design, Synthesis, and Anti-Proliferative Evaluation.
    Elwan A; Abdallah AE; Mahdy HA; Dahab MA; Taghour MS; Elkaeed EB; Mehany ABM; Nabeeh A; Adel M; Alsfouk AA; Elkady H; Eissa IH
    Molecules; 2022 Aug; 27(15):. PubMed ID: 35956997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pyridine-derived VEGFR-2 inhibitors: Rational design, synthesis, anticancer evaluations, in silico ADMET profile, and molecular docking.
    Saleh NM; Abdel-Rahman AA; Omar AM; Khalifa MM; El-Adl K
    Arch Pharm (Weinheim); 2021 Aug; 354(8):e2100085. PubMed ID: 33948983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations.
    Aziz NAAM; George RF; El-Adl K; Mahmoud WR
    Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200465. PubMed ID: 36403198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and anticancer evaluation of N-sulfonylpiperidines as potential VEGFR-2 inhibitors, apoptotic inducers.
    Elgammal WE; Halawa AH; Eissa IH; Elkady H; Metwaly AM; Hassan SM; El-Agrody AM
    Bioorg Chem; 2024 Apr; 145():107157. PubMed ID: 38340473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors.
    El-Adl K; El-Helby AA; Sakr H; El-Hddad SSA
    Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000068. PubMed ID: 32510731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis, in vitro antiproliferative evaluation and in silico studies of new VEGFR-2 inhibitors based on 4-piperazinylquinolin-2(1H)-one scaffold.
    Hassan A; Badr M; Abdelhamid D; Hassan HA; Abourehab MAS; Abuo-Rahma GEA
    Bioorg Chem; 2022 Mar; 120():105631. PubMed ID: 35091289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
    Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
    Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel quinoxaline-based VEGFR-2 inhibitors to halt angiogenesis.
    Ismail MMF; Shawer TZ; Ibrahim RS; Allam RM; Ammar YA
    Bioorg Chem; 2023 Oct; 139():106735. PubMed ID: 37531818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel VEGFR-2 inhibitors as antiangiogenic and apoptotic agents via paracrine and autocrine cascades: Design, synthesis, and biological evaluation.
    Abdel Rahman DE; Fouad MA; Mohammed ER; El-Zoheiry HH; Abdelrasheed Allam H
    Bioorg Chem; 2023 Oct; 139():106678. PubMed ID: 37354661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2-Phenylquinazolin-4(3H)-one scaffold as newly designed, synthesized VEGFR-2 allosteric inhibitors with potent cytotoxicity through apoptosis.
    Elrayess R; Elgawish MS; Nafie MS; Ghareb N; Yassen ASA
    Arch Pharm (Weinheim); 2023 Jun; 356(6):e2200654. PubMed ID: 37002183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Iodoquinazoline-derived VEGFR-2 and EGFR
    Mohamed AA; El-Hddad SSA; Aljohani AKB; Khedr F; Alatawi OM; Keshek DE; Ahmed S; Alsulaimany M; Almadani SA; El-Adl K; Hanafy NS
    Bioorg Chem; 2024 Feb; 143():107062. PubMed ID: 38150938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation.
    Marzouk AA; Abdel-Aziz SA; Abdelrahman KS; Wanas AS; Gouda AM; Youssif BGM; Abdel-Aziz M
    Bioorg Chem; 2020 Sep; 102():104090. PubMed ID: 32683176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.